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Cancer-associated mutations reveal a novel
role for EpCAM as an inhibitor of cathepsinL and tumor cell invasion
Narendra V. Sankpal1* , Taylor C. Brown1,2, Timothy P. Fleming3, John M. Herndon1, Anusha A. Amaravati1,
Allison N. Loynd1 and William E. Gillanders1,2*

Abstract
Background: EpCAM (Epithelial cell adhesion molecule) is often dysregulated in epithelial cancers. Prior studies
implicate EpCAM in the regulation of oncogenic signaling pathways and epithelial-to-mesenchymal transition. It
was recently demonstrated that EpCAM contains a thyroglobulin type-1 (TY-1) domain. Multiple proteins with TY-1
domains are known to inhibit cathepsin-L (CTSL), a cysteine protease that promotes tumor cell invasion and
metastasis. Analysis of human cancer sequencing studies reveals that somatic EpCAM mutations are present in up
to 5.1% of tested tumors.
Methods: The Catalogue of Somatic Mutations in Cancer (COSMIC) database was queried to tabulate the position
and amino acid changes of cancer associated EpCAM mutations. To determine how EpCAM mutations affect cancer
biology we studied C66Y, a damaging TY-1 domain mutation identified in liver cancer, as well as 13 other cancerassociated EpCAM mutations. In vitro and in vivo models were used to determine the effect of wild type (WT) and
mutant EpCAM on CTSL activity and invasion. Immunoprecipitation and localization studies tested EpCAM and CTSL
protein binding and determined compartmental expression patterns of EpCAM mutants.
Results: We demonstrate that WT EpCAM, but not C66Y EpCAM, inhibits CTSL activity in vitro, and the TY-1 domain
of EpCAM is responsible for this inhibition. WT EpCAM, but not C66Y EpCAM, inhibits tumor cell invasion in vitro
and lung metastases in vivo. In an extended panel of human cancer cell lines, EpCAM expression is inversely
correlated with CTSL activity. Previous studies have demonstrated that EpCAM germline mutations can prevent
EpCAM from being expressed at the cell surface. We demonstrate that C66Y and multiple other EpCAM cancerassociated mutations prevent surface expression of EpCAM. Cancer-associated mutations that prevent EpCAM cell
surface expression abrogate the ability of EpCAM to inhibit CTSL activity and tumor cell invasion.
Conclusions: These studies reveal a novel role for EpCAM as a CTSL inhibitor, confirm the functional relevance of
multiple cancer-associated EpCAM mutations, and suggest a therapeutic vulnerability in cancers harboring EpCAM
mutations.
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Background
Epithelial cell adhesion molecule (EpCAM) is a transmembrane glycoprotein that is expressed at the basolateral membrane of human epithelial tissues [1]. EpCAM
is also highly overexpressed in many human epithelial
cancers including colorectal, breast, gastric, prostate,
ovarian, and lung cancer [2, 3]. EpCAM was the first human tumor-associated antigen to be identified using
monoclonal antibodies [4] and has been the target of
monoclonal antibody therapy in colorectal cancer [5, 6].
The monoclonal antibody Catumaxomab, which targets
EpCAM and causes an anti-cancer immune response,
has been approved for the treatment of malignant ascites
in Europe [7]. Despite these developments, further research is needed to improve our understanding of
EpCAM’s role in epithelial cancers and its potential as a
therapeutic target. Recently, we and others have demonstrated that overexpressed EpCAM modulates oncogenic
signaling pathways including ERK [8], NF-κβ [9], AP-1
[10], NF-κβ [9] and Wnt/β-catenin [11–13] pathways.
EpCAM expression can differentially regulate oncogenic
signaling pathways and invasion depending on the cancer type [14]. These studies suggest that the precise role
of EpCAM in cancer biology remains to be elucidated.
At the structural level, EpCAM contains a well characterized thyroglobulin-type-1 (TY-1) domain [15]. The
EpCAM TY-1 domain is located between amino acids
63 and 135 in the extracellular region (Fig. 1). There are
17 proteins with TY-1 domains in the human genome
(Fig. S1A). TY-1 domains are characterized by a unique
sequence motif of 60–80 residues containing six conserved cysteine residues, forming three disulfide bonds

(Fig. S1B) [16]. TY-1 domains are conserved in a number of species, and multiple proteins with TY-1 domains
function as cathepsin family protease inhibitors [17],
(Table S1). Proteins with TY-1 domains have been
shown to inhibit cathepsin-L (CTSL), a protease implicated in tumor invasion [18, 19].
CTSL is frequently overexpressed in many cancers,
and CTSL expression has been associated with higher
histologic tumor grade and metastatic potential [20].
CTSL is secreted by tumor cells [21, 22] and is capable
of degrading extracellular matrix proteins and promoting tumor cell invasion [23–25]. Because of its frequent
overexpression and prominent role in metastasis, CTSL
inhibitors have been the focus of multiple preclinical investigations. CTSL inhibition has demonstrated promising results [20]. Interestingly, both EpCAM [26, 27] and
CTSL [28, 29] are known to be secreted into the tumor
microenvironment and are present in the serum of human cancer patients. To date, the potential impact of
EpCAM on CTSL activity has not been studied.
The Cancer Genome Atlas (TCGA) and other high
throughput cancer sequencing studies have dramatically
improved our understanding of the genetic basis of cancer. Functional analyses of specific cancer-associated
mutations have provided critical insights into how mutated proteins contribute to the biology of cancer, and
how to best target these proteins. To date, over 130 coding, cancer-associated mutations in the EpCAM gene
have been identified (Fig. 1). Studies reveal that somatic
mutations in EpCAM are present in up to 5.1% of some
tested cancer cohorts, including squamous and melanoma skin cancers. EpCAM mutations have also been
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Fig. 1 Cancer-associated EpCAM mutations. Histogram (top) shows location and frequency of EpCAM cancer-associated mutations as reported in
COSMIC (https://cancer.sanger.ac.uk/cosmic). Protein schematic (bottom) indicates EpCAM protein structure. EpCAM is a type-1 transmembrane
protein with a signal peptide (SP, green), an N-terminal domain (ND, blue), a thyroglobulin type-1 domain (TY-1, red), a C domain (CD, tan), a
transmembrane domain (TM, gray), and an intracellular domain (EpIC, purple). Domain positions noted as reported by Pavsic et al. [10]. The
EpCAM C66Y mutation in the TY-1 domain is predicted to be highly damaging by Polyphen2 (http://genetics.bwh.harvard.edu/pph2/)
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observed in metastatic lesions and other cancers at a frequency of 1–2% (Fig. S1C). No reports to date have investigated the potential role of EpCAM mutations in
human cancer, although germline mutations in EpCAM
impact cellular localization and are associated with congenital tufting enteropathy and Lynch syndrome [30,
31]. In the current report we demonstrate for the first
time that secreted wild type (WT) EpCAM inhibits
extracellular CTSL activity. More importantly, we demonstrate that EpCAM cancer-associated mutations alter
EpCAM cellular function and localization, abrogate the
ability of EpCAM to inhibit CTSL activity, and impact
CTSL-driven cancer cell invasion.

Methods
EpCAM mutation analysis

To determine the position, amino acid change, and occurrences of somatic EpCAM coding mutations in cancer, we queried the Catalogue of Somatic Mutations in
Cancer (COSMIC) publicly available database (https://
cancer.sanger.ac.uk/cosmic) at Sanger Institute [32] and
tabulated reported mutations. To determine the frequency of EpCAM mutations in tested cancer cohorts,
we analyzed 178 non-redundant datasets including 47,
005 samples in the cBioPortal for Cancer Genomics [33].
Cell line mutations in EpCAM were analyzed from the
Cancer Cell Line Encyclopedia (CCLE) publicly available
database at the Broad Institute (https://portals.
broadinstitute.org/ccle). The potential impact of mutations of interest on EpCAM protein structure and function was analyzed in silico using PolyPhen-2 [34].
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RNA interference

Lentiviral-mediated RNA interference was performed as
previously described [8]. shRNA sequences targeting
murine cathepsin-L were provided by the McDonnell
Genome Institute at Washington University in St Louis.
Specific sequences used for RNA interference are
detailed in Table S2.
Plasmid constructs and site directed mutagenesis

The full-length open reading frame of EpCAM was amplified from the MCF-10A mammary epithelial cell line.
The nucleotide sequence was confirmed with NCBI reference sequence NM_002354. The DNA sequence was
subcloned into both pcDNA3 (HindIII-XbaI restriction
sites) and the retroviral vector pBABE (BamHI-SalI restriction after mutating BamHI sites). EpCAM deletion
mutants were generated by PCR amplification and
cloned as c-terminal 3X Flag tag fusion protein as shown
in Fig. 3e. C66Y EpCAM and other EpCAM cancerassociated mutation constructs were generated using
synthetic gene fragments from Integrated DNA Technologies (IDT, Coralville, IA). For example, C66Y
EpCAM was generated as a G-block fragment (197G >
A; substitution position 197, G➞A). Other mutations
were generated based on tumor DNA mutation information available at COSMIC [32] or cBioPortal [33] databases. For EpCAM-GFP fusion constructs generation,
EpCAM cDNA was amplified from pCDNA3 vector and
subcloned at the N-terminal EGFP of Lentiviral vector
pLL3.7 at NheI and AgeI restriction sites.
Retroviral and Lentiviral transduction

Cell lines

All cell lines were obtained from the American Type
Culture Collection (ATCC, Rockville, MD) and used at a
low passage number with the exception of WHIM-3.
WHIM-3 is a breast cancer cell line isolated from a
patient-derived xenograft. WHIM-3 was provided by the
patient derived xenograft (PDX) core at Washington
University of School of Medicine (WUSM). All cell lines
were maintained in RPMI or DMEM supplemented with
10% FBS and antibiotics (GIBCO BRL, Grand Island,
NY). All cell lines were tested for mycoplasma and
maintained in ciprofloxacin (10 μg/mL media).

Phoenix-ECO packaging cells were transfected when
nearly confluent with 2.5 μg of pBABE-Puro-EpCAM
using FuGENE-HD (Promega, Madison, WI). Forty eight
hours after transfection viral supernatants were collected, filtered through 0.45 μm filters, and then added
to B16-F10, A549 and other cells in media containing
8 μg/mL protamine sulfate. After two successive retroviral infections, cells were grown for 48 h and selected in
puromycin for 2 weeks. Lentiviral vector pLL3.7 was obtained from addgene (Plasmid#11795). EpCAM-EGFP
fused DNA was transiently transfected in HEK-293 T
cells using FuGENE6 or stably transduced as described
before [8].

Recombinant proteins

Recombinant EpCAM-Fc (Gln24-Lys265-IgG1Pro100Lys300, carrier free) and recombinant CTSL (Glu113Val333) were purchased from R&D Systems (Minneapolis, MN). Recombinant EpCAM-Fc was reconstituted as
recommended by manufacturer and stored at -80 °C in
aliquots.

Flow cytometry

EpCAM expression levels were measured by flow cytometry using PE-labeled EpCAM antibody. Expression was
quantified as mean fluorescence intensity (MFI) using a
FACScan flow cytometer and FlowJo 10.7.1 software
(BD Biosciences, San Jose, CA).
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Cathepsin-L activity assay

Cells were suspended in ice-cold lysis buffer (400 mM
sodium phosphate buffer, pH 6.0, 75 mM NaCl, 4 mM
EDTA, and 0.25% Triton X-100) and incubated on ice
for 30 min. Lysates were centrifuged at 15,000 rpm for
20 min at 4 °C. Protein concentration was determined by
the BCA protein assay kit (Pierce, Rockford, IL). CTSL
activity was measured by fluorometric assay [35]. Briefly,
10 μg of total cell lysate was diluted in 100 μL of 0.34 M
sodium acetate buffer, pH 5.5, containing 2 mM EDTA,
and 4 mM dithiothreitol (DTT). To discriminate between CTSL and cathepsin-B activities, a selective
cathepsin-B inhibitor, CA074 (Sigma), was added at a
final concentration of 5 μM and pre-incubated for 15
min at 37 °C. Fluorogenic substrate Z-Phe-Arg-AMC
(Sigma) was added to a final concentration of 5 μM and
samples were incubated for an additional 30–60 min at
37 °C. Fluorescence of the degradation product, 7amino-4-methylcoumarin (7-AMC), was measured at an
excitation wavelength of 370 nm and an emission
wavelength of 460 nm, using a spectrometer (BioTeK).
Cysteine protease inhibitor L-trans-epoxy-succinyl-leucylamido-(4-guanidino)-butane (E64, Sigma) was used as
a CTSL inhibitor at 50 μM concentration.
Protein immunoblots

Cells were washed with ice-cold PBS and lysed in RIPA
cell lysis buffer with a protease inhibitor cocktail
(Cat#9806, Cell Signaling Technology, Danvers, MA).
Protein concentrations were determined by BCA protein
assay (Cat#23227, Pierce, Rockford, IL). Approximately
20–30 μg of protein was subjected to SDS-PAGE
(NuPAGE, Life Technologies), and transferred by electrophoresis to a PVDF membrane. EpCAM (C-10
cat#25308) and actin-HRP (C4, Cat#sc-47,778) antibodies were obtained from Santa Cruz Biotechnology
(Santa Cruz, CA). CTSL antibody (Cat#ab6314) was obtained from AbCAM (Cambridge, MA). Signal detection
was performed using the SuperSignal West Pico chemiluminescent immunodetection system (Cat#34580,
Thermo Scientific, Rockford, IL). To quantify band density, immunoblots were developed on film, scanned, and
pixels in each band were measured using Image J
software.
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antibodies or control IgG at 4 °C with 25 μl of Protein
A/G)-Agarose. The immunobeads were washed 3 times
in lysis buffer and then eluted in 50 μL of 2× reducing
sample
buffer,
boiled,
and
proceeded
for
immunoblotting.
Immunofluorescence and confocal microscopy

Lentivirus transduced MDCK or transiently transfected
HEK-293 T cells with EpCAM-EGFP constructs were
lightly trypsinized after 48 h and plated on a glass bottom 35 mm dish with serum-free Opti-MEM media
(ThermoFisher Scientific, Grand Island, New York).
Cells were visualized and captured with a fluorescence
microscope (EVOS digital inverted microscope at 20X or
40X magnifications). Duplicate cell culture was used for
data measurements on a Zeiss LSM 880 microscope
equipped with the AiryScan detector, an Argon laser
(Melles-Griot) for 488 nm excitation and a Zeiss PlanApochromat 63 × 1.4 NA DIC M27 Oil objective. The
microscope is equipped with temperature and CO2 controls that were kept at 37 °C and 5%, respectively.
EpCAM ELISA

Transiently transfected HEK-293 T or tumor cell lines
were plated in 6-well plate overnight and cultured in
serum free Opti-MEM media (Cat# 11058021, ThermoFisher Scientific, Grand Island, New York). After 48 h,
conditioned media was used as a source of secreted/soluble EpCAM. Human EpCAM DuoSet ELISA kit
(Cat#DY960) was used from R&D Systems Inc., Minneapolis, MN as recommended.
Invasion assays

Cells (4 × 104) were added to Matrigel transwell invasion
chambers or control transwell chambers (BD Biosciences, San Jose, CA) and incubated for 24–72 h with
chemoattractant media (Clonetics, Walkersville, MD)
supplemented with growth factors. Cells invading
through the Matrigel or control membranes were fixed
using 70% ethanol, stained with 0.1% crystal violet, and
photographed in four fields to cover the entire area.
Cells were counted from all fields by a scientist blinded
to the experimental conditions.
Animal experiments

Immunoprecipitation

For protein extraction, cells were scraped in PBS supplemented with 1 mM Na3VO4, centrifuged and resuspended in lysis buffer (20 mM Tris, pH 7.4, 150 mM
NaCl, 0.25% NP-40, 0.2% Triton-X, 1 mM Na3VO4, and
1 mM PMSF). Five hundred μg of protein was precleared
with 50 μl Protein A/G-Agarose (sc-2003, Santa Cruz
Biotechnology, Santa Cruz, CA) for 30 min. Precleared
lysates were then incubated for 1 h using 2 μg of specific

Tumor cell expansion for cathepsin-L activity assays
were done by xenografting stable lines in 4–6 weeks old
female NOD-SCID gamma (NSG) IL2Rgammanull mice
(The Jackson Laboratory, Bar Harbor, Maine). Tumor
cells were transduced with pBABE-puro retroviruses to
express EpCAM or GFP/empty vector as described earlier. Cells were re-suspended in DMEM, 1 × 107 per
100 μL. Before tumor cell injection, the mice were anesthetized with 2.5–4% isoflurane under continuous
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infusion via a nose mask. Cells were injected subcutaneously then allowed to expand in mice for 2–3 weeks.
Two mice were used per cell line to establish cell lines.
When the tumor growth reached 0.5–1 cm3, tumors
were removed aseptically, minced, filtered and plated in
appropriate growth media. After 2 days, tumor cells were
selected in puromycin containing media for 1 week.
These lines were used within 5–8 passages for CTSL activity assay experiments.
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cancer-associated mutation identified in a liver cancer
specimen. The cysteine residue is part of a critical disulfide bond, and the C66Y mutation is likely to extensively
perturb EpCAM structure [15] and thereby disrupt function of the EpCAM TY-1 domain (Fig. 1). Analysis by
PolyPhen-2 [34] predicts the C66Y mutation to have a
highly damaging effect (data not shown) on protein
structure and function. We demonstrate below that the
C66Y mutation also impacts EpCAM cellular
localization as well.

Tumor challenge/lung metastasis assay

Six to ten weeks old female C57BL/6 mice were purchased from Charles River Laboratories (Wilmington,
MA) and were used for all lung metastasis experiments. Mice were housed at an institutional animal
facility. B16-F10 cells (5 × 104) were re-suspended in
200 μL PBS. For tail vein injections, mice were immobilized in a rodent holder and kept under heating
lamp for 1 min to dilate blood vessels. Two hundred
μL cell suspensions were injected via tail vein into
mice using hypodermic syringes. Animals were monitored weekly. Five mice per group were used in individual studies, and each study was repeated at least
three times. Three weeks following tumor challenge,
the mice were euthanized by CO2 asphyxiation or
cervical dislocation according to the approved IACUC
protocol. Lung nodules were photographed and
counted using a dissecting microscope.
Statistical analysis

Numerical data are presented as the mean values ± the
standard deviation. Statistical significance was evaluated
using the Student’s t test. A p-value < 0.05 was considered to be statistically significant. GraphPad PRISM
(GraphPad Software Inc., La Jolla, CA) was used for statistical analysis of all experiments.

Results
Somatic EpCAM mutations are present in a significant
number of human cancers

To analyze somatic EpCAM mutations in human cancers, we queried the COSMIC database as well as 178
non-redundant datasets including 47,005 samples in the
cBioPortal for Cancer Genomics [32, 33]. We identified
115 unique somatic/missense coding EpCAM mutations
(Fig. 1). Depending on the dataset and cancer type,
EpCAM mutations are present at a frequency between 0
to 5.13% in human cancers (Fig. S1C). Cell line mutations of EpCAM were also analyzed from the CCLE
database. We found 33 mutations, including silent,
frame shift, and missense mutations (Fig. S1D). We
identified multiple cancer-associated mutations which
may affect the overall structure and function of EpCAM.
C66Y EpCAM is an exemplary TY-1 domain EpCAM

WT, but not C66Y EpCAM, inhibits tumor cell invasion
in vitro and in vivo

EpCAM has been implicated in the regulation of cancer
invasion. To investigate the role of cancer-associated
EpCAM mutations, we initially focused on C66Y. We
expressed WT, or C66Y EpCAM, in the human WHIM3 breast and murine PyMT BO-1 mammary cancer cell
lines. Both cell lines have minimal to null endogenous
EpCAM expression and an invasive, mesenchymal
phenotype with high CTSL activity. Cells were transduced with retroviruses expressing either GFP (control),
WT EpCAM, or C66Y EpCAM. Total protein and cell
surface expression levels were confirmed by immunoblot
and flow cytometry. Total WT and C66Y expression
levels were similar, but the C66Y mutant is not
expressed on the cell surface (Fig. S2 A-C). Expression
of WT EpCAM decreased in vitro invasion in both cell
lines approximately 70% compared to cells expressing
C66Y EpCAM or GFP (Fig. 2a, b). To extend these findings, we transduced WT or C66Y EpCAM in B16-F10
cells and performed both in vitro and in vivo studies.
B16-F10 has minimal to null EpCAM expression (Fig.
2b), is known to be highly invasive, and is dependent on
CTSL activity for migration and invasion [36]. Specific
ablation of CTSL altered morphology, decreased B16F10 invasion in vitro, confirming that this cell line is
dependent on CTSL for invasion (Fig. S3A-C). We transduced B16-F10 cells with WT or C66Y EpCAM and selected stable clones of the cell lines. We confirmed that
expression of WT or C66Y EpCAM was comparable in
these cell lines by protein immunoblot (Fig. 2b and S2A,
C right panel). Expression of WT, but not C66Y
EpCAM, significantly decreased B16-F10 tumor cell invasion in vitro (Fig. 2b, right panel), and the number of
lung cancer metastases following tumor challenge
in vivo (Fig. 2c, Fig. S3D). CTSL promotes tumor cell invasion and metastasis by degradation of the interstitial
matrix and basement membranes. C66Y EpCAM failed
to suppress CTSL-mediated lung metastasis in vivo (Fig.
2c). These results suggest that EpCAM expression has
the potential to regulate cathepsin-L mediated invasion
in the B16-F10 cell line.
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Fig. 2 Wild type, but not C66Y EpCAM, inhibits tumor cell invasion in vitro and in vivo. a WHIM-3 and PyMT BO-1 breast cancer cell lines were
transduced with GFP, wild type EpCAM, or C66Y EpCAM. Invasion was assessed in vitro using Matrigel chambers. b B16-F10 cells were transduced
with GFP, wild type EpCAM, or C66Y (EpCAM colony 1 and 2). Protein expression is shown by immunoblot (left). Invasion (right) was assessed
in vitro using Matrigel chambers. c B16-F10 cells were transduced with GFP, wild type EpCAM, or C66Y EpCAM. Transduced cells were injected
into animals by tail vein, and the lungs were harvested 2 weeks later. Representative lungs samples are shown (left). Lung metastases were
counted using a dissecting microscope by two independent researchers (right). All experiments were performed at least three times. Full-length
blots are presented in Supplementary Fig. 5

WT, but not C66Y EpCAM, inhibits CTSL activity

Based on the known role of TY-1 domains in the regulation of CTSL (Fig. S1A, B, Table S1), we tested the hypothesis that EpCAM can inhibit CTSL. First, we
measured EpCAM expression and CTSL activity in a
panel of cell lines. EpCAM expression was assessed by
flow cytometry, and CTSL activity was assessed using a
fluorescent substrate. We observed a striking inverse
correlation between EpCAM expression and CTSL activity (Fig. 3a & b). As previously discussed, EpCAM [26,
27] and CTSL [28, 29] are both secreted into the extracellular space where they likely come in contact in the
tumor microenvironment. To determine if soluble
EpCAM can inhibit CTSL activity, we incubated recombinant EpCAM-Fc with tumor derived (see methods)
SKOV3 cell lysates as a source of CTSL (SKOV3 cells
have the highest CTSL activity (Fig. 3a) in the panel of

tested cell lines). Recombinant EpCAM-Fc decreased
CTSL activity in a dose dependent manner, and at 10
ng/mL, CTSL activity was suppressed approximately
60% (Fig. 3c). We also tested the ability of cancer cell
lines transduced with EpCAM to inhibit CTSL. In cell
line A549, which has minimal endogenous EpCAM expression (Fig. 3a), WT, but not C66Y EpCAM was able
to significantly inhibit CTSL activity (Fig. 3d). To evaluate the potential role of the EpCAM TY-1 domain in the
inhibition of CTSL, we generated EpCAM deletion mutants (Fig. 3e). Stably transduced A549 cell lines with
EpCAM deletion mutants shows roughly equivalent expression of wildtype EpCAM and EpCAM truncation
mutants with C-terminal Flag Tag. The EpCAM 265
truncation mutant, which lacks the transmembrane domain, is secreted into the supernatant (Fig. S4A). Stable
A549 cells were further cultured in serum-free Opti-
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Fig. 3 Wild type, but not C66Y EpCAM, can inhibit CTSL activity. a, b EpCAM expression negatively correlates with CTSL activity in a panel of
cancer cell lines. EpCAM expression was measured by flow cytometry, and CTSL activity was measured using a fluorescent substrate. c
Recombinant EpCAM inhibits CTSL activity. Increasing doses of recombinant EpCAM were added to conditioned media from SKOV-3 cells (source
of CTSL). CTSL activity was measured after 30 min. d Wild type, but not C66Y EpCAM, inhibits CTSL activity. A549 cells were stably transduced
with GFP, wild type EpCAM or C66Y EpCAM. Endogenous CTSL activity was measured. e, f Wild type EpCAM and EpCAM deletion mutants
containing the TY-1 domain, can inhibit CTSL activity. A549 cells were stably transduced with the indicated EpCAM deletion mutants, and
endogenous CTSL activity was measured

MEM media for 24 h and assayed for CTSL activity.
Only EpCAM deletion mutants with intact TY-1 domains (EpCAM 314,288,265) were capable of inhibiting
CTSL activity (Fig. 3f). As previously reported [15] and
shown here, the cysteine at residue 66 forms a critical
disulfide bond in the EpCAM TY-1 domain. The C66Y
mutation likely impacts protein structure and CTSL inhibition. Taken together, these studies confirm that
EpCAM is capable of inhibiting CTSL activity, presumably via the TY-1 domain.

assays. We used the MDA-MB-468 breast cancer cell
line, which expresses moderate amounts of both EpCAM
and CTSL (Fig. 3a). MDA-MB-468 cell lysates were incubated with IgG, anti-EpCAM, or anti-CTSL antibodies, and immunoprecipitated proteins were
immunoblotted for EpCAM or CTSL. EpCAM immunoprecipitation pulls down CTSL (Fig. 4a and Fig. S5), and
CTSL immunoprecipitation pulls down EpCAM (Fig. 4b
and Fig. S5), demonstrating a physical interaction between these proteins.

WT EpCAM physically interacts with CTSL

Many cancer-associated mutations prevent EpCAM cell
surface expression and secretion and abrogate EpCAM’s
ability to inhibit CTSL

The ability of TY-1 domain proteins to inhibit CTSL activity typically depends on a physical interaction between
the TY-1 domain protein and CTSL. To determine if
EpCAM can physically interact with CTSL, we performed immunoprecipitation and protein immunoblot

EpCAM is a type-I transmembrane glycoprotein, which
is predominantly localized on the cell surface. The extracellular domain of EpCAM is secreted (and/or cleaved)
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Fig. 4 Wild type EpCAM physically interacts with CTSL. a MDA-MB-468 cell lysates were immunoprecipitated with EpCAM (clone C-10) or control
(IgG) antibody as described in methods section. EpCAM immunoprecipitation pulls down CTSL. b Cell lysates were immunoprecipitated with
CTSL or control (IgG) antibody. CTSL immunoprecipitation pulls down EpCAM. Full length blots are presented in Supplementary Fig. 5

and is detectable in cell culture media and the serum
and ascites of cancer patients. Soluble/secreted EpCAM
(EpEX) is a 242 amino acid (aa) fragment lacking the
signal peptide (23 aa), transmembrane domain (23 aa),
and cytoplasmic tail (26 aa) [13]. CTSL, while typically
expressed in the endosome, has also been shown to be
secreted by tumor cells and potentiates invasion in multiple cancer types [37, 38]. A study of congenital tufting
enteropathy patients demonstrated that some EpCAM
germline mutations can alter cellular trafficking and
localization of EpCAM protein to the cell surface [30].
In that study, multiple germline EpCAM mutations prevented EpCAM expression at the cell surface.
To investigate whether cancer-associated EpCAM mutations affect its cellular localization, and/or its potential
to inhibit CTSL, we cloned multiple cancer-associated
EpCAM mutations in expression vectors alone, or fused
to GFP at the C-terminal, and tracked EpCAM
localization in vitro. Partial proteolysis of EpCAM is
known and is expected with the dominant EpEX protein
when transfected in HEK-293 T cells [39]. Immunoblot
analysis demonstrates that the majority of EpCAM mutants are expressed at similar levels at WT EpCAM and
that the TY-1 domain of EpCAM remains intact when
secreted (Fig. S4B & C).
As shown in Fig. 5a, flow cytometry and confocal microscopy demonstrate that representative EpCAM-WT
and EpCAM-M115T localize to the cell surface of epithelial MDCK cells, whereas EpCAM-C66Y and
EpCAM-L240A localize in the cytosolic compartments.
To verify that soluble EpCAM can inhibit CTSL activity,
HEK-293 T cells were then transfected with GFP-tagged
EpCAM mutants and cultured in serum free media.

After 48 h, conditioned media was collected to measure
soluble EpCAM levels by ELISA and/or to test the ability
of conditioned media to inhibit CTSL activity. As expected, EpCAM mutants that are not expressed at the
cell surface were not detected in culture media by ELISA
(Fig. 5b, right), and these conditioned medias could not
inhibit CTSL activity from SKOV3 media (Fig. 5c, right).
In contrast, WT EpCAM and EpCAM mutants
expressed at the cell surface were readily detected in culture media (Fig. 5b, left), and conditioned media robustly
inhibited CTSL activity (Fig. 5c, left). Together, these results demonstrate that secreted EpCAM inhibits secreted
CTSL activity, while cancer-associated EpCAM mutations that prevent cell surface expression also prevent
the ability to inhibit CTSL activity.
To confirm and extend these findings, we tested A549
lung cancer cells under multiple conditions. CTSL activity is required for A549 invasion [40] and at baseline
A549 cells are less invasive compared to other CTSLsecreting cells. Addition of CTSL-rich SKOV3 conditioned media enhanced A549 invasion 3-fold, and this
was abrogated by the CTSL inhibitor E64 (Fig. 5d, last 2
bar graphs). This confirms previous reports that CTSL
contributes to A549 invasion. To assess the effect of
cancer-associated EpCAM mutations on A549 invasion,
A549 cells were plated on Matrigel transwell invasion
chambers for 2 h followed by the addition of conditioned
media from transfected HEK-293 T cells expressing WT
or mutant EpCAM. After 30 min, CTSL-rich SKOV3
conditioned media was added and invasion was monitored over 24 h. As expected, WT and cancer-associated
EpCAM mutants expressed at the cell surface suppressed invasion, while cancer-associated EpCAM

Sankpal et al. BMC Cancer

(2021) 21:541

Page 9 of 13

A. EpCAM localization
MDCK-EpCAM wildtype

B. Soluble EpCAM

35000

EpCAM (pg/mL)

30000
25000
20000
15000
10000

MCF-7

C66Y

V196A

Y186C

R44H

60
40
20

A5-CM

V196A

MCF-7

C66Y

R138X

Y186C

R44H

L240A

L141G

N198H

C135G

M294I

V285del

Y174C

T172M

0

(+) (-)
Control

Intracellular

D.Invasion

1500

Number of cells Invaded

R138X

L240A

80

Cell Surface

MDCK-EpCAM L240A

(+) (-)
Control

100

WT

MDCK-EpCAM C66Y

Intracellular

C. CTSL activity

120

M115T

Cathepsin L activity (%RFU)

Cell Surface

L141G

C135G

M294I

N198H

Y174C

V285del

T172M

WT

MDCK-EpCAM M115T

M115T

0

HEK-293T

5000

1250
1000
750
500
250

MDCK-EpCAM:
EpCAM-IgG1-PE

SK-E64

V196A

SK-Sup

C66Y

Y186C

R44H

R138X

L240A

L141G

C135G

N198H

M294I

V285del

Y174C

T172M

WT

MDCK:IgG1-PE

M115T

0

(+) (-)

EpCAM-GFP

Cell Surface

Intracellular

Control

Fig. 5 Cancer associated EpCAM mutations prevents EpCAM-CTSL localization, interaction and Cathepsin L mediated invasion. a MDCK cells were
transduced with WT, M115T, C66Y, and L240A EpCAM and surface expression was analyzed by flow cytometry or confocal microscopy,
respectively. b GFP-tagged EpCAM mutants were transfected in 12 well culture plates into HEK-293 T cells. 500uL of Opti-mem media was added
to harvest secreted EpCAM in conditioned media after 48 h and assayed by ELISA to measure soluble EpCAM. c After 48 h of culturing, 1-mL of
conditioned media was collected from 6-well SKOV3 culture as a source of soluble CTSL. Conditioned media from transformed HEK-293 T cells
was used as a source of soluble EpCAM. CTSL activity was determined as discussed in methods. CTSL activity for secreted/cell surface EpCAM was
normalized with EpCAM whole cell extracts blot as shown in supplementary Fig. S4B. A5-CM (A549 conditioned media serves as a control). d
A549 cells were plated on Matrigel for 6 h. Conditioned media and soluble EpCAM were added, followed by soluble CTSL. After 24 h cells were
tabulated to measure invasion
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mutants with no expression at the cell surface did not
affect invasion. Together, our findings suggest that soluble/secreted EpCAM can suppress extracellular CTSL
protease activity via its TY-1 domain, while cancerassociated EpCAM mutants that are not expressed on
the cell surface do not retain this function.

Discussion
EpCAM is overexpressed in many epithelial cancers, and
plays a complex role in cancer biology, stimulating or
inhibiting diverse cancer signaling pathways depending
on the cancer type [8–10]. There are 17 proteins with
TY-1 domains in the human genome (Fig. S1A). TY-1
domains are dependent on three conserved disulfide
bonds (Fig. S1B), creating a structure that can function
as a cathepsin family protease inhibitor [41, 42]. In studies performed here, we demonstrate that WT EpCAM
has the ability to inhibit CTSL, and that this inhibition is
dependent on the intact TY-1 domain of EpCAM. C66Y
is a cancer-associated EpCAM mutation that disrupts an
important disulfide bond in the EpCAM TY-1 domain.
The findings reported here provide important insights
into the biology of this and other cancer-associated
EpCAM mutations.
Cathepsin proteases play a key role in tissue remodeling, tumor invasion, and metastasis. CTSL promotes
tumor cell invasion and metastasis by degradation of the
interstitial matrix and basement membranes [43]. Cathepsin protease activity is frequently dysregulated during neoplastic transformation, and increased activity
within the tumor microenvironment leads to cancer progression, proliferation, metastasis, and drug resistance.
CTSL is a powerful lysosomal cysteine proteinase, and
CTSL expression and activity is markedly increased in
advanced cancers [44]. Forced expression of CTSL is associated with increased migration, invasion, and chemotherapy resistance [36, 45, 46], and inhibition of CTSL
activity decreased tumor growth and invasion [47]. As
such, a role for WT EpCAM in the regulation of CTSL
in normal epithelia and/or cancer (as demonstrated
here) is consistent with the known roles for EpCAM in
the regulation of both epithelial-to-mesenchymal transition (EMT) and tumor cell invasion.
EpCAM mutations have been identified in many human epithelial cancer types. In the present study we focused on C66Y EpCAM, a mutation resulting in a
profound structural and functional alteration in the
EpCAM TY-1 domain. We expect other cysteine mutations such as C135G in the TY-1 domain will disrupt
EpCAM structure and interaction with CTSL. We also
studied 13 other cancer-associated EpCAM mutations
and discovered that approximately 50% of these mutations prevented EpCAM cell surface expression. In
addition to these nonsynonymous mutations, EpCAM
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expression is often silenced in cancer cells by promoter
methylation, histone modification, and/or aberrant transcription factor signaling [48]. EpCAM is silenced in
various cancer types [49, 50], and silencing may exceed
the observed rate of mutations. Our data suggest that
EpCAM gene silencing is likely associated with increased
CTSL activity. Therefore, EpCAM gene silencing may
represent an additional therapeutic opportunity to target
CTSL, although further studies would be needed.
A previous report showed preferential accumulation of
EpCAM C66Y mutant in the endoplasmic reticulum
[30]. We show a similar pattern here (Fig. 5a). Unlike
C66Y, the L240A mutant does not concentrate in the
endoplasmic reticulum (ER), but is expressed diffusely in
the cytoplasm (Fig. 5a). It has been suggested that the
C66Y mutant may cause aberrant EpCAM dimerization,
protein misfolding, and ER retention [30, 51]. A L240A
mutation would not affect disulfide bond formation,
which is critical to EpCAM structure, and may have
minimal impact on protein folding. L240A is located
near the transmembrane domain (Fig. 1) and could
affect EpCAM membrane anchoring and cell surface
expression.
Based on a detailed crystal structure analysis, the first
loop of the EpCAM TY-1 domain interacts with the Cterminal domain of adjacent EpCAM to form EpCAM
cis-dimers [15]. This suggests that the EpCAM TY-1 domain may not be available to inhibit CTSL activity when
dimerized on the cell surface due to steric hindrances.
However, EpCAM is frequently present as a monomer
under different experimental conditions [15, 52–54], and
EpCAM is known to be cleaved and secreted by cancer
cells as shown by us (Fig. 5) and by others [13]. We
demonstrate here that soluble EpCAM inhibits CTSL activity in a dose dependent manner (Fig. 3c) and that this
inhibitory effect is abrogated by deletion of the TY-1 domain of EpCAM (Fig. 3e). These findings are consistent
with other studies demonstrating that thyroglobulin domains in other proteins can inhibit cathepsins (Table
S1). Together, these results suggest that EpCAM likely
inhibits CTSL in a soluble and/or monomeric state.
These studies reveal a novel role for EpCAM in the
regulation of CTSL, but also have potential therapeutic
implications as well. Cancers harboring cancerassociated EpCAM mutations and/or EpCAM silencing
may have increased CTSL activity. While many cancers
demonstrate overexpression of CTSL, it is unclear if this
directly corresponds to increased CTSL and metastatic
activity. Laboratory techniques have been developed that
measure cathepsin activity in tissue specimens, but
greater specificity is needed for CTSL [55], and these are
not routinely performed. EpCAM mutations could potentially serve as a biomarker of increased CTSL activity
in the tumor microenvironment and identify patients
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that would benefit from protease inhibitors targeting
CTSL. Initial clinical trials of protease inhibitors (predominantly matrix metalloprotease inhibitors) showed
limited efficacy due to off target activity causing significant drug toxicity [20]. However, more recent preclinical
studies have identified and tested multiple different types
of cathepsin inhibitors that have been shown to specifically target cathepsin subtypes with less toxicity [56].
Taken together, our findings and these recent preclinical
studies suggest that CTSL inhibition in cancers harboring EpCAM mutations may prove to be an effective
strategy.

Conclusions
Our study demonstrates a molecular mechanism of
tumor progression in EpCAM mutated tumor cells.
CTSL is often overexpressed or activated in advanced
epithelial cancers. To date, 115 coding, somatic EpCAM
mutations have been reported and deposited in public
databases [32, 33]. Our study demonstrates that some of
these mutations drive EpCAM accumulation in cytosol
compartments and prevent membrane expression. TY-1
domain mutations also disrupted CTSL binding. In an
era where genomic testing is being increasingly used to
drive biomarker-driven therapeutic decisions in patient
care, additional study is required to understand the role
of EpCAM mutations in cancer biology, and the potential to target these mutations with existing and/or novel
therapies.
Abbreviations
CTSL: Cathepsin-L; EpCAM: Epithelial Cell Adhesion Molecule; TY1: Thyroglobulin-type-1 domain; PDX: Patient derived xenograft
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WHIM-3 and B, PyMT BO-1 breast cancer cell lines were transduced with
GFP, wild type EpCAM, or C66Y EpCAM. Flow cytometry data is shown.
Additional file 3: Supplementary Fig. S3. Specific ablation of CTSL
decreases B16-F10 invasion. A-C, To specifically ablate CTSL, B16-F10 cells
were stably transduced with a lentivirus expressing shRNAs targeting
CTSL and stable clones were selected with variable degrees of CTSL ablation. Specific ablation of CTSL results in (A) altered cell morphology, (B)
decreased CTSL activity, and (C) decreased invasion. The CTSL inhibitor E64 serves as a positive control in the CTSL activity and invasion assays. D,
B16-F10 cells stably transduced with GFP or EpCAM were injected into
mice by tail vein. Lungs were harvested after 10 days. The number of
lung metastases was assessed using a dissecting microscope.
Additional file 4: Supplementary Fig. S4. A. EpCAM deletion
mutants. (Fig. 3e, f) were expressed at similar levels in A549 cells whole
cell extract. EpCAM deletion mutant 265 was secreted in collected media.
All constructs were expressed as C-terminal flag tag. Anti-flag antibody
was used to develop the immunoblot. EpCAM 291F without signal domain, thus not secreted protein was used as control (not shown in Fig.
3e, f). Supplementary Fig. S4. B, C. Immunoblots of tested EpCAM and
EpCAM mutants. B. EpCAM-WT and mutants (Fig. 5b) were expressed in
HEK-293 T cells. Immunoblot using whole cell extract (WCE) shows surface
expressing mutants (left panel) are expressed at similar levels as intracellular mutants (right panel). C. EpCAM mutants expressed as soluble/secreted protein (Fig. 5b, EpEX, 242aa) in cultured HEK-293 T cells were
minimally cleaved with an intact TY-1 domain.
Additional file 5: Supplementary Fig. S5. Immunoblots of tested
EpCAM and EpCAM mutants. A. Full immunoblot scans of EpCAM and
EpCAM C66Y expressed in B16-F10 cells (Fig. 2b) and coimmunoprecipitation of EpCAM and CTSL in MDA-MB-468 cells. (Fig. 4a
and b) is shown.
Additional file 6: Table S1. TY-1 proteins inhibits CTSL family members.
Table showing proteins with TY-1 domains have been reported to inhibit
cathepsin family with references.
Additional file 7: Table S2. Mouse lentiviral CTSL shRNA. Table with
lentiviral shRNA sequence used in the current study related to Fig. S3, AC.

Acknowledgements
The authors would like to thank Washington University School of Medicine
for support and assistance throughout the research.

Supplementary Information
The online version contains supplementary material available at https://doi.
org/10.1186/s12885-021-08239-z.
Additional file 1: Supplementary Fig. S1. A, B. Human proteins with
TY-1 domains. A. Seventeen human proteins contain highly conserved
TY-1 domains. SMOC-1-2; Testican 1–3; CD74; EpCAM, TACSTD2; IGFBP1–
6; and NID1–2. B. Thyroglobulin type-1 domain characterized, alignment
of representative TY-1 domain with consensus conserved cysteine residues shown in box. Supplementary Fig. S1. C. Cancer-associated
EpCAM mutations. Analysis of 178 datasets including 47,005 nonredundant samples from the Cancer Genomics Portal (www.cbioportal.
org) reveals cancer-associated EpCAM mutations in approximately 0–5%
of analyzed tumor sets. Datasets where the prevalence of cancerassociated mutations are > 1% are shown. Supplementary Fig. S1. D.
Tested cell lines and EpCAM mutations. The Cancer Cell Line
Encyclopedia (CCLE) was queried (https://portals.broadinstitute.org/ccle).
A total of 33 mutations in 31 cell lines were identified, including silent,
frame shift, and missense mutations. EpCAM mutations were not identified in tested cell lines.
Additional file 2: Supplementary Fig. S2. A. Wild type, but not C66Y
EpCAM, inhibits tumor cell invasion in vitro and in vivo. WHIM-3 and
PyMT BO-1 breast cancer cell lines were transduced with GFP, wild type
EpCAM, or C66Y EpCAM. Immunoblot data is shown. B. Wild type, but
not C66Y EpCAM, inhibits tumor cell invasion in vitro and in vivo. A,

Authors’ contributions
NVS and WEG were responsible for study conception, design, and
supervision. NVS, AAA, and ANL performed the in vitro experiments. NVS and
JMH performed animal experiments. NVS, TCB, TPF, and WEG wrote the
manuscript. All authors have read and approved the manuscript.

Funding
This work was supported by a grant from Susan G. Komen for the Cure
(BCTR0707917). Siteman Cancer Center shared resources were used
(P30CA91842). This funding support was used for laboratory experimental
work but played no role in the design, data collection, analysis, and
interpretation of data or in writing the manuscript.

Availability of data and materials
Human EpCAM mutations were accessed through the publicly available
Catalogue of Somatic Mutations in Cancer (COSMIC, https://cancer.sanger.ac.
uk/cosmic) at the Sanger Institute. Cell line EpCAM mutations were accessed
through the publicly available Cancer Cell Line Encyclopedia (CCLE, https://
portals.broadinstitute.org/ccle) at the Broad Institute. The functional impact
of the C66Y EpCAM mutation in the TY-1 domain was predicted by Polyphen2 (http://genetics.bwh.harvard.edu/pph2/). The datasets used and/or analyzed during the current study are available from the corresponding author
on reasonable request.

Sankpal et al. BMC Cancer

(2021) 21:541

Declarations
Ethics approval and consent to participate
Animal experiments followed the NIH guidelines (NIH Pub. No. 85–23,
revised 1996) and have been approved by the Animal Protection and Use
Committee of Washington University School of Medicine.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Author details
1
Department of Surgery, Washington University School of Medicine, 660
South Euclid Avenue, Campus Box 8109, Saint Louis, MO 63110, USA.
2
Siteman Cancer Center, Washington University School of Medicine, St. Louis,
MO, USA. 3Norton Thoracic Institute, St. Joseph’s Hospital and Medical
Center, 124 W. Thomas Road, Phoenix 85013, AZ, USA.
Received: 3 November 2020 Accepted: 22 April 2021

References
1. Momburg F, Moldenhauer G, Hammerling GJ, Moller P.
Immunohistochemical study of the expression of a Mr 34,000 human
epithelium-specific surface glycoprotein in normal and malignant tissues.
Cancer Res. 1987;47(11):2883–91.
2. Spizzo G, Went P, Dirnhofer S, Obrist P, Simon R, Spichtin H, et al. High EpCAM expression is associated with poor prognosis in node-positive breast
cancer. Breast Cancer Res Treat. 2004;86(3):207–13. https://doi.org/10.1023/B:
BREA.0000036787.59816.01.
3. Went PT, Lugli A, Meier S, Bundi M, Mirlacher M, Sauter G, et al. Frequent
EpCAM protein expression in human carcinomas. Hum Pathol. 2004;35(1):
122–8. https://doi.org/10.1016/j.humpath.2003.08.026.
4. Herlyn M, Steplewski Z, Herlyn D, Koprowski H. Colorectal carcinomaspecific antigen detection by means of monoclonal antibodies. Proc Natl
Acad Sci U S A. 1979;76(3):1438–42. https://doi.org/10.1073/pnas.76.3.1438.
5. Sears HF, Atkinson B, Mattis J, Ernst C, Herlyn D, Steplewski Z, et al. Phase-I
clinical trial of monoclonal antibody in treatment of gastrointestinal
tumours. Lancet. 1982;1(8275):762–5. https://doi.org/10.1016/s0140-6736(82
)91811-6.
6. Riethmuller G, Holz E, Schlimok G, Schmiegel W, Raab R, Hoffken K, et al.
Monoclonal antibody therapy for resected Dukes’ C colorectal cancer:
seven-year outcome of a multicenter randomized trial. J Clin Oncol. 1998;
16(5):1788–94. https://doi.org/10.1200/JCO.1998.16.5.1788.
7. Linke R, Klein A, Seimetz D. Catumaxomab: clinical development and future
directions. MAbs. 2010;2(2):129–36. https://doi.org/10.4161/mabs.2.2.11221.
8. Sankpal NV, Fleming TP, Sharma PK, Wiedner HJ, Gillanders WE. A doublenegative feedback loop between EpCAM and ERK contributes to the
regulation of epithelial-mesenchymal transition in cancer. Oncogene. 2017;
36(26):3706–17. https://doi.org/10.1038/onc.2016.504.
9. Sankpal NV, Fleming TP, Gillanders WE. EpCAM modulates NF-kappaB
signaling and interleukin-8 expression in breast cancer. Mol Cancer Res.
2013;11(4):418–26. https://doi.org/10.1158/1541-7786.MCR-12-0518.
10. Sankpal NV, Mayfield JD, Willman MW, Fleming TP, Gillanders WE. Activator
protein 1 (AP-1) contributes to EpCAM-dependent breast cancer invasion.
Breast Cancer Res. 2011;13(6):R124. https://doi.org/10.1186/bcr3070.
11. Gostner JM, Fong D, Wrulich OA, Lehne F, Zitt M, Hermann M, et al. Effects
of EpCAM overexpression on human breast cancer cell lines. BMC Cancer.
2011;11(1):45. https://doi.org/10.1186/1471-2407-11-45.
12. Yamashita T, Budhu A, Forgues M, Wang XW. Activation of hepatic stem cell
marker EpCAM by Wnt-beta-catenin signaling in hepatocellular carcinoma.
Cancer Res. 2007;67(22):10831–9. https://doi.org/10.1158/0008-5472.CAN-070908.
13. Maetzel D, Denzel S, Mack B, Canis M, Went P, Benk M, et al. Nuclear
signalling by tumour-associated antigen EpCAM. Nat Cell Biol. 2009;11(2):
162–71. https://doi.org/10.1038/ncb1824.
14. Fagotto F, Aslemarz A. EpCAM cellular functions in adhesion and migration,
and potential impact on invasion: a critical review. Biochim Biophys Acta
Rev Cancer. 1874;2020(2):188436.

Page 12 of 13

15. Pavsic M, Guncar G, Djinovic-Carugo K, Lenarcic B. Crystal structure and its
bearing towards an understanding of key biological functions of EpCAM.
Nat Commun. 2014;5(1):4764. https://doi.org/10.1038/ncomms5764.
16. Molina F, Bouanani M, Pau B, Granier C. Characterization of the type-1
repeat from thyroglobulin, a cysteine-rich module found in proteins from
different families. Eur J Biochem. 1996;240(1):125–33. https://doi.org/1
0.1111/j.1432-1033.1996.0125h.x.
17. Lenarcic B, Bevec T. Thyropins--new structurally related proteinase inhibitors.
Biol Chem. 1998;379(2):105–11.
18. Meh P, Pavsic M, Turk V, Baici A, Lenarcic B. Dual concentration-dependent
activity of thyroglobulin type-1 domain of testican: specific inhibitor and
substrate of cathepsin L. Biol Chem. 2005;386(1):75–83. https://doi.org/10.1
515/BC.2005.010.
19. Lenarcic B, Krishnan G, Borukhovich R, Ruck B, Turk V, Moczydlowski E.
Saxiphilin, a saxitoxin-binding protein with two thyroglobulin type 1
domains, is an inhibitor of papain-like cysteine proteinases. J Biol Chem.
2000;275(20):15572–7. https://doi.org/10.1074/jbc.M001406200.
20. Sudhan DR, Siemann DW. Cathepsin L targeting in cancer treatment.
Pharmacol Ther. 2015;155:105–16. https://doi.org/10.1016/j.pharmthera.2015.
08.007.
21. Denhardt DT, Greenberg AH, Egan SE, Hamilton RT, Wright JA. Cysteine
proteinase cathepsin L expression correlates closely with the metastatic
potential of H-ras-transformed murine fibroblasts. Oncogene. 1987;2(1):55–9.
22. Gottesman MM, Sobel ME. Tumor promoters and Kirsten sarcoma virus
increase synthesis of a secreted glycoprotein by regulating levels of
translatable mRNA. Cell. 1980;19(2):449–55. https://doi.org/10.1016/00928674(80)90519-X.
23. Baricos WH, Zhou Y, Mason RW, Barrett AJ. Human kidney cathepsins B and
L. characterization and potential role in degradation of glomerular
basement membrane. Biochem J. 1988;252(1):301–4. https://doi.org/10.1
042/bj2520301.
24. Chambers AF, Colella R, Denhardt DT, Wilson SM. Increased expression of
cathepsins L and B and decreased activity of their inhibitors in metastatic,
ras-transformed NIH 3T3 cells. Mol Carcinog. 1992;5(3):238–45. https://doi.
org/10.1002/mc.2940050311.
25. Colella R, Jackson T, Goodwyn E. Matrigel invasion by the prostate cancer
cell lines, PC3 and DU145, and cathepsin L+B activity. Biotech Histochem.
2004;79(3–4):121–7. https://doi.org/10.1080/10520290400010572.
26. Seeber A, Braicu I, Untergasser G, Nassir M, Fong D, Botta L, et al. Detection
of soluble EpCAM (sEpCAM) in malignant ascites predicts poor overall
survival in patients treated with catumaxomab. Oncotarget. 2015;6(28):
25017–23. https://doi.org/10.18632/oncotarget.4496.
27. Seeber A, Martowicz A, Spizzo G, Buratti T, Obrist P, Fong D, et al. Soluble
EpCAM levels in ascites correlate with positive cytology and neutralize
catumaxomab activity in vitro. BMC Cancer. 2015;15(1):372. https://doi.org/1
0.1186/s12885-015-1371-1.
28. Zhang W, Yang HC, Wang Q, Yang ZJ, Chen H, Wang SM, et al. Clinical
value of combined detection of serum matrix metalloproteinase-9,
heparanase, and cathepsin for determining ovarian cancer invasion and
metastasis. Anticancer Res. 2011;31(10):3423–8.
29. Chen Q, Fei J, Wu L, Jiang Z, Wu Y, Zheng Y, et al. Detection of cathepsin B,
cathepsin L, cystatin C, urokinase plasminogen activator and urokinase
plasminogen activator receptor in the sera of lung cancer patients. Oncol
Lett. 2011;2(4):693–9. https://doi.org/10.3892/ol.2011.302.
30. Schnell U, Kuipers J, Mueller JL, Veenstra-Algra A, Sivagnanam M, Giepmans
BN. Absence of cell-surface EpCAM in congenital tufting enteropathy. Hum
Mol Genet. 2013;22(13):2566–71. https://doi.org/10.1093/hmg/ddt105.
31. Pathak SJ, Mueller JL, Okamoto K, Das B, Hertecant J, Greenhalgh L, et al.
EPCAM mutation update. Variants associated with congenital tufting
enteropathy and lynch syndrome. Hum Mutat. 2019;40(2):142–61. https://
doi.org/10.1002/humu.23688.
32. Tate JG, Bamford S, Jubb HC, Sondka Z, Beare DM, Bindal N, et al. COSMIC:
the catalogue of somatic mutations in Cancer. Nucleic Acids Res. 2019;
47(D1):D941–7. https://doi.org/10.1093/nar/gky1015.
33. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio
cancer genomics portal: an open platform for exploring multidimensional
cancer genomics data. Cancer Discov. 2012;2(5):401–4. https://doi.org/10.11
58/2159-8290.CD-12-0095.
34. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P,
et al. A method and server for predicting damaging missense mutations.
Nat Methods. 2010;7(4):248–9. https://doi.org/10.1038/nmeth0410-248.

Sankpal et al. BMC Cancer

(2021) 21:541

35. Werle B, Staib A, Julke B, Ebert W, Zladoidsky P, Sekirnik A, et al.
Fluorometric microassays for the determination of cathepsin L and
cathepsin S activities in tissue extracts. Biol Chem. 1999;380(9):1109–16.
https://doi.org/10.1515/BC.1999.138.
36. Yang Z, Cox JL. Cathepsin L increases invasion and migration of B16
melanoma. Cancer Cell Int. 2007;7(1):8. https://doi.org/10.1186/1475-2867-78.
37. Felbor U, Dreier L, Bryant RA, Ploegh HL, Olsen BR, Mothes W. Secreted
cathepsin L generates endostatin from collagen XVIII. EMBO J. 2000;19(6):
1187–94. https://doi.org/10.1093/emboj/19.6.1187.
38. Dykes SS, Fasanya HO, Siemann DW. Cathepsin L secretion by host and
neoplastic cells potentiates invasion. Oncotarget. 2019;10(53):5560–8.
https://doi.org/10.18632/oncotarget.27182.
39. Schnell U, Kuipers J, Giepmans BN. EpCAM proteolysis: new fragments with
distinct functions? Biosci Rep. 2013;33(2):e00030. https://doi.org/10.1042/
BSR20120128.
40. Han ML, Zhao YF, Tan CH, Xiong YJ, Wang WJ, Wu F, et al. Cathepsin L
upregulation-induced EMT phenotype is associated with the acquisition of
cisplatin or paclitaxel resistance in A549 cells. Acta Pharmacol Sin. 2016;
37(12):1606–22. https://doi.org/10.1038/aps.2016.93.
41. Novinec M, Kordis D, Turk V, Lenarcic B. Diversity and evolution of the
thyroglobulin type-1 domain superfamily. Mol Biol Evol. 2006;23(4):744–55.
https://doi.org/10.1093/molbev/msj082.
42. Mihelic M, Turk D. Two decades of thyroglobulin type-1 domain research.
Biol Chem. 2007;388(11):1123–30. https://doi.org/10.1515/BC.2007.155.
43. Palermo C, Joyce JA. Cysteine cathepsin proteases as pharmacological
targets in cancer. Trends Pharmacol Sci. 2008;29(1):22–8. https://doi.org/10.1
016/j.tips.2007.10.011.
44. Lankelma JM, Voorend DM, Barwari T, Koetsveld J, Van der Spek AH, De
Porto AP, et al. Cathepsin L, target in cancer treatment? Life Sci. 2010;86(7–
8):225–33. https://doi.org/10.1016/j.lfs.2009.11.016.
45. Sui H, Shi C, Yan Z, Wu M. Overexpression of Cathepsin L is associated with
chemoresistance and invasion of epithelial ovarian cancer. Oncotarget.
2016;7(29):45995–6001. https://doi.org/10.18632/oncotarget.10276.
46. Joyce JA, Baruch A, Chehade K, Meyer-Morse N, Giraudo E, Tsai FY, et al.
Cathepsin cysteine proteases are effectors of invasive growth and
angiogenesis during multistage tumorigenesis. Cancer Cell. 2004;5(5):443–
53. https://doi.org/10.1016/S1535-6108(04)00111-4.
47. Bell-McGuinn KM, Garfall AL, Bogyo M, Hanahan D, Joyce JA. Inhibition of
cysteine cathepsin protease activity enhances chemotherapy regimens by
decreasing tumor growth and invasiveness in a mouse model of multistage
cancer. Cancer Res. 2007;67(15):7378–85. https://doi.org/10.1158/0008-5472.
CAN-07-0602.
48. van der Gun BT, de Groote ML, Kazemier HG, Arendzen AJ, Terpstra P,
Ruiters MH, et al. Transcription factors and molecular epigenetic marks
underlying EpCAM overexpression in ovarian cancer. Br J Cancer. 2011;
105(2):312–9. https://doi.org/10.1038/bjc.2011.231.
49. Soysal SD, Muenst S, Barbie T, Fleming T, Gao F, Spizzo G, et al. EpCAM
expression varies significantly and is differentially associated with prognosis
in the luminal B HER2(+), basal-like, and HER2 intrinsic subtypes of breast
cancer. Br J Cancer. 2013;108(7):1480–7. https://doi.org/10.1038/bjc.2013.80.
50. Ralhan R, Cao J, Lim T, Macmillan C, Freeman JL, Walfish PG. EpCAM nuclear
localization identifies aggressive thyroid cancer and is a marker for poor
prognosis. BMC Cancer. 2010;10(1):331. https://doi.org/10.1186/1471-2407-1
0-331.
51. Paliwal P, Gupta J, Tandon R, Sharma N, Titiyal JS, Kashyap S, et al.
Identification and characterization of a novel TACSTD2 mutation in
gelatinous drop-like corneal dystrophy. Mol Vis. 2010;16:729–39.
52. Trebak M, Begg GE, Chong JM, Kanazireva EV, Herlyn D, Speicher DW.
Oligomeric state of the colon carcinoma-associated glycoprotein GA733-2
(Ep-CAM/EGP40) and its role in GA733-mediated homotypic cell-cell
adhesion. J Biol Chem. 2001;276(3):2299–309. https://doi.org/10.1074/jbc.
M004770200.
53. Pavsic M, Lenarcic B. Expression, crystallization and preliminary X-ray
characterization of the human epithelial cell-adhesion molecule
ectodomain. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2011;67(Pt
11):1363–6. https://doi.org/10.1107/S1744309111031897.
54. Balzar M, Briaire-de Bruijn IH, Rees-Bakker HA, Prins FA, Helfrich W, de Leij L,
et al. Epidermal growth factor-like repeats mediate lateral and reciprocal
interactions of Ep-CAM molecules in homophilic adhesions. Mol Cell Biol.
2001;21(7):2570–80. https://doi.org/10.1128/MCB.21.7.2570-2580.2001.

Page 13 of 13

55. Blum G, von Degenfeld G, Merchant MJ, Blau HM, Bogyo M. Noninvasive
optical imaging of cysteine protease activity using fluorescently quenched
activity-based probes. Nat Chem Biol. 2007;3(10):668–77. https://doi.org/10.1
038/nchembio.2007.26.
56. Sadaghiani AM, Verhelst SH, Gocheva V, Hill K, Majerova E, Stinson S, et al.
Design, synthesis, and evaluation of in vivo potency and selectivity of
epoxysuccinyl-based inhibitors of papain-family cysteine proteases. Chem
Biol. 2007;14(5):499–511. https://doi.org/10.1016/j.chembiol.2007.03.010.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.

